Xenetic Biosciences, Inc. is a biopharmaceutical company based in Lexington, Town of, MA, dedicated to advancing innovative immune-oncology technologies. With a focus on proprietary technology platforms, the company aims to target neutrophil extracellular traps (NETs), which are known to drive cancer progression and metastasis, as well as contribute to resistance to chemotherapy, checkpoint inhibitors, and radiotherapy.
Utilizing their DNase I Oncology Platform, Xenetic Biosciences aims to improve cancer therapies and address multiple high-value cancer indications, including pancreatic cancer and other solid tumors. Through strategic partnerships, research agreements, and a strong pipeline of potential treatments, the company is committed to making significant advancements in the field of oncology.
Generated from the website